Roche Holding (RHHBY)
(Delayed Data from OTC)
$34.97 USD
+0.08 (0.23%)
Updated Dec 24, 2024 12:24 PM ET
3-Hold of 5 3
B Value C Growth D Momentum B VGM
Price, Consensus and EPS Surprise
RHHBY 34.97 +0.08(0.23%)
Will RHHBY be a Portfolio Killer in December?
Zacks Investment Research is releasing its prediction for RHHBY based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for RHHBY
Roche's Prasinezumab Misses Goal in Parkinson's Disease Study
SRPT Finishes Enrolment in Late-Stage Study for Rare Muscular Disorder
RHHBY: What are Zacks experts saying now?
Zacks Private Portfolio Services
Roche Gets Approval for Vabysmo PFS in EU for Three Retinal Diseases
Regeneron Down 15.5% Year to Date: How to Play the Stock?
Pharma Stock Roundup: LLY's Zepbound Success, FDA Updates for MRK, JNJ
Other News for RHHBY
RAPT rockets 180% on licensing deal, $150M private placement
Lazard Managed Equity Volatility Portfolio Q3 2024 Commentary
Jazz Pharmaceuticals: Should Sing A Better Tune In 2025
RAPT rockets 180% on licensing deal, $150M private placement (update)
Impax International Sustainable Economy Fund Q3 2024 Commentary